Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Bevacizumab, and Cyclophosphamide in High Grade Ovarian Cancer with MRD
NCT06083844Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2023
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 1 year and Progression-Free Survival at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06083844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083844.